Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer
24 oct. 2019 08h15 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based weight loss solutions company focused on commercializing the Obalon Balloon System, the first...
Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss
22 oct. 2019 08h15 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric...
Obalon Announces Repayment of All Long-Term Debt and Regaining of Compliance with NASDAQ Listing Requirement
03 oct. 2019 09h00 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved...
Obalon Engages Helmuth T. Billy, MD as Medical Director for its First Company-Owned Weight Loss Treatment Center
03 sept. 2019 09h00 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved...
Obalon Therapeutics Inc. Announces Closing of $16.6 Million Public Offering
06 août 2019 16h01 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (Nasdaq: OBLN) (the “Company”), a vertically integrated medical technology company with the first and only FDA-approved...
Obalon Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
05 août 2019 09h00 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering
02 août 2019 08h48 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (Nasdaq: OBLN) (the “Company”), a vertically integrated medical technology company with the first and only FDA-approved...
Obalon Announces Reverse Stock Split Effective Today
24 juil. 2019 08h53 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Announces Second Quarter 2019 Financial Results
24 juil. 2019 07h45 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Enters Into Commercial Lease for its First Company-Owned Retail Weight Loss Center
23 juil. 2019 08h30 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...